Cesar B. De Moraes
Sao Paulo, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center.
Journal: Clinics (Sao Paulo, Brazil)
Published: March 20, 2026
Position statement of the Biotechnology Committee of the Brazilian Society of Rheumatology on the interchangeability of originator and biosimilar biologics in immune-mediated rheumatic diseases.
Journal: Advances in rheumatology (London, England)
Published: October 06, 2024
Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
Journal: PLoS neglected tropical diseases
Published: May 23, 2021
Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR.
Journal: Clinical rheumatology
Published: January 06, 2019
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
Journal: Advances in rheumatology (London, England)
Published: July 18, 2018
Periodontitis Response to Anti-TNF Therapy in Ankylosing Spondylitis.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: September 24, 2015
Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease.
Journal: Vaccine
Published: March 02, 2012
Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics).
Journal: Revista brasileira de reumatologia
Published: November 16, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026